Novo Nordisk A/S
NVO
$44.96
$0.571.28%
NYSE
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 14.87B | 12.34B | 11.74B | 11.69B | 11.02B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.87B | 12.34B | 11.74B | 11.69B | 11.02B |
| Cost of Revenue | 2.09B | 2.21B | 2.27B | 1.95B | 1.82B |
| Gross Profit | 12.78B | 10.13B | 9.48B | 9.74B | 9.20B |
| SG&A Expenses | 2.03B | 2.67B | 2.47B | 2.87B | 2.27B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 16.28M | -12.63M | -- | 3.50M | -1.97M |
| Total Operating Expenses | 5.71B | 6.84B | 6.54B | 6.60B | 5.54B |
| Operating Income | 9.15B | 5.49B | 5.21B | 5.09B | 5.47B |
| Income Before Tax | 9.55B | 5.33B | 4.00B | 5.14B | 5.22B |
| Income Tax Expenses | 2.09B | 1.14B | 863.28M | 1.11B | 1.13B |
| Earnings from Continuing Operations | 7.46B | 4.19B | 3.13B | 4.03B | 4.10B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.46B | 4.19B | 3.13B | 4.03B | 4.10B |
| EBIT | 9.15B | 5.49B | 5.21B | 5.09B | 5.47B |
| EBITDA | 9.69B | 5.71B | 5.72B | 5.73B | 6.00B |
| EPS Basic | 1.68 | 0.94 | 0.71 | 0.91 | 0.92 |
| Normalized Basic EPS | 1.34 | 0.82 | 0.77 | 0.72 | 0.74 |
| EPS Diluted | 1.68 | 0.94 | 0.70 | 0.91 | 0.92 |
| Normalized Diluted EPS | 1.34 | 0.82 | 0.77 | 0.72 | 0.73 |
| Average Basic Shares Outstanding | 4.44B | 4.44B | 4.44B | 4.44B | 4.44B |
| Average Diluted Shares Outstanding | 4.45B | 4.45B | 4.45B | 4.45B | 4.45B |
| Dividend Per Share | -- | 1.24 | 0.00 | 0.57 | -- |
| Payout Ratio | 72.72% | 0.00% | 83.29% | -- | 121.49% |